

# Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/TB5DE24F8939EN.html>

Date: February 2020

Pages: 69

Price: US\$ 3,500.00 (Single User License)

ID: TB5DE24F8939EN

## Abstracts

Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020

### SUMMARY

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 10 and 3 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM),

Metastatic Colorectal Cancer, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Lung Cancer, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Uveal Melanoma, Non-Hodgkin Lymphoma, Osteolytic Bone Metastasis, Pancreatic Cancer, Retinitis Pigmentosa (Retinitis) and Triple-Negative Breast Cancer (TNBC).

The latest report Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)

The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Celldex Therapeutics Inc

Celon Pharma SA

Dong-A Socio Holdings Co Ltd

Eli Lilly and Co

Elsalys Biotech SA

F. Hoffmann-La Roche Ltd

HEC Pharm Co Ltd

Hope Biosciences Inc

Incyte Corp

Meryx Inc

Novithera SAS

Ono Pharmaceutical Co Ltd

Qurient Co Ltd

Rgenix Inc

SignalChem Lifesciences Corp

TamRx LLC

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles

Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune

**Diseases and Infectious Disease - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**CT-413 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**DA-4501 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Drugs to Inhibit MERTK for Hematological and Solid Tumors - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**ELB-031 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**HOPE-777 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products****Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones****Featured News & Press Releases**

Apr 08, 2019: Dong-A ST's investigational drug posts positive study results

Apr 03, 2019: Rgenix presents pre-clinical data on RGX-019 at the 2019 AACR Annual Meeting

Apr 01, 2019: Rgenix to present abstract on RGX-019 at the 2019 AACR Annual Meeting

Nov 10, 2018: Celldex presents emerging MerTK antibody program at the Society for

Immunotherapy of Cancer's 33rd annual meeting

Dec 29, 2017: Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodulatory Agent and TYRO3, AXL, MER (TAM) Inhibitor

Nov 08, 2017: Ignyta Announces New Data Highlighting Immune Modulation of RXDX-106 at the Society for Immunotherapy of Cancer Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indications, H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by Celldex Therapeutics Inc, H1 2020  
Pipeline by Celon Pharma SA, H1 2020  
Pipeline by Dong-A Socio Holdings Co Ltd, H1 2020  
Pipeline by Eli Lilly and Co, H1 2020  
Pipeline by Elsalys Biotech SA, H1 2020  
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020  
Pipeline by HEC Pharm Co Ltd, H1 2020  
Pipeline by Hope Biosciences Inc, H1 2020  
Pipeline by Incyte Corp, H1 2020  
Pipeline by Meryx Inc, H1 2020  
Pipeline by Novithera SAS, H1 2020  
Pipeline by Ono Pharmaceutical Co Ltd, H1 2020  
Pipeline by Qurient Co Ltd, H1 2020  
Pipeline by Rgenix Inc, H1 2020  
Pipeline by SignalChem Lifesciences Corp, H1 2020  
Pipeline by TamRx LLC, H1 2020  
Dormant Projects, H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Top 10 Indications, H1 2020  
Number of Products by Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Celldex Therapeutics Inc  
Celon Pharma SA  
Dong-A Socio Holdings Co Ltd  
Eli Lilly and Co  
Elsalys Biotech SA  
F. Hoffmann-La Roche Ltd  
HEC Pharm Co Ltd  
Hope Biosciences Inc  
Incyte Corp  
Meryx Inc  
Novithera SAS  
Ono Pharmaceutical Co Ltd  
Qurient Co Ltd  
Rgenix Inc  
SignalChem Lifesciences Corp  
TamRx LLC

## I would like to order

Product name: Tyrosine Protein Kinase Mer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/TB5DE24F8939EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TB5DE24F8939EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970